Megan Hodge's Back Pain

This is a Vertex news story, published by Science News, that relates primarily to Vertex Pharmaceuticals news.

Vertex news

For more Vertex news, you can click here:

more Vertex news

disease research news

For more disease research news, you can click here:

more disease research news

Science News news

For more news from Science News, you can click here:

more news from Science News

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about

Megan Hodge

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest pain resilience news, chronic back pain news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

chronic pain

Science News

•

A next-gen pain drug shows promise, but chronic suffers need more options

Summary

Nutrition label

81% Informative

In the United States , chronic pain affects about 1 in 5 adults and nearly 1 in 3 people ages 65 and older.

Vertex Pharmaceuticals is seeking regulatory approval for a new drug, suzetrigine, that looks promising in clinical trials.

If approved, it would introduce the first entirely new class of pain therapies in decades .

About 20 percent of all U.S. adults experience chronic pain, defined as pain on most days or every day during the previous three months .

Vertex ’s new pain compound, suzetrigine, could be the first to deliver in a race to target specific sodium ion channels found on pain-sensing nerve cells.

In December , Vertex reported that suzetrigine seems to alleviate pain in people with diabetic peripheral neuropathy, a kind of pain that stems from nerve damage typically in the hands and feet.

New genetic discoveries may lead to more targets, such as sodium channels specific to pain-sensing neurons.

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

possibly offensive

Hate speech